We are developing a new class of therapeutics derived from sRNA-signatures
PIPELINE OF THERAPEUTIC PROGRAMS FOCUS ON AREAS WITH KNOWN HETEROGENEITY
Inflammation
Fibrosis
Neurodegeneration
ESTABLISHED ECOSYSTEM OF BIOTECH COMPANIES, RESEARCH ORGANIZATIONS, FOUNDATIONS AND ACADEMIC INSTITUTIONS
Academic collaborators
Drug developers
Technology providers
"Gatehouse Bio has taken a unique approach to deciphering roles for the entire spectrum of non-coding small RNAs. By invoking unbiased analytic methods, GHB has identified novel diagnostic and functionally significant disease related effects. "
— Director, Genome Science Institute
"Gatehouse’s technology and machine learning generated algorithms have the potential to be Transformational for drug R&D. Their approach is disruptive in the pharmaceutical arena and will expedite precision medicine to patients in great need of disease-modifying therapeutics."
— Director of translational neuroscience
"The role of small RNAs in regulating gene expression is understood; GHB’s innovative approach and robust methodology provide insights into genes and pathways that drive disease. The outcome of this pivotal work can help define the next step towards precision medicine and novel targets. "
— Senior Director Emerging Innovations Unit
Want to learn more?
We have established a global network of collaborators across academia, industry and patient advocacy groups, who share our vision and commitment to patients.
Thanks for your interest! Please fill out the form below to download a copy of our case study
David Salzman, PhD
As founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. He was previously a postdoctoral fellow at the Yale School of Medicine and a scientist at Biogen, where he gained experience in developing clinical and preclinincal biomarker, PK/PD, and diagnostic platforms. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology. He earned his PhD in Molecular Biology and Biochemistry from the University of Connecticut and a BS in Environmental Science from the University of Hartford.
If you have any questions or would like to set up a call to talk about a future partnership, we would love to hear from you. Please fill out the form below and one of our members will be in touch.